secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-09-14T12:00:18+00:00
Accession:  0001493152-26-042483
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir announces preclinical osteosarcoma data: Telomir-Zn inhibits growth in human and canine cell lines
--------------------------------------------------------------------------------

- Ohio State study: Telomir-Zn inhibited growth in HOS (human), D17 (canine), and Abrams (canine) osteosarcoma cell lines at similar low drug concentrations.
- Company assessing potential in vivo canine osteosarcoma efficacy study with Ohio State; TNBC Phase 1/2 enrollment advancing toward site initiation.
- Lead investigator Shay Bracha, DVM, DACVIM (Oncology); findings support translational development in both veterinary and human osteosarcoma.
- TNBC program remains immediate focus under active FDA-cleared IND; osteosarcoma is a parallel Track 2 development pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/0001493152-26-042483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer